| Description | Olendalizumab (ALXN1007), a humanized IgG2-G4-κ antibody derived from mice, specifically targets Complement protein C5a with a binding affinity (K i) of 60 pM. This compound is designed to inhibit the complement inflammatory pathway. Additionally, olendalizumab is utilized in the research of complement-mediated disorders triggered by the coronavirus [1] [2]. |
| molecular weight | N/A |
| CAS | 2210314-30-8 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 years |